Edaravone

Edaravone (IPA: /ɛdəˈrævoʊn/), also known by its brand name Radicava or MCI-186, is a medication primarily used for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Etymology

The name "Edaravone" is derived from the chemical name 3-methyl-1-phenyl-2-pyrazolin-5-one.

Usage

Edaravone is used to slow the progression of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord. It is administered intravenously and works by relieving the effects of oxidative stress, which is believed to be a significant factor in the death of nerve cells in people with ALS.

Related Terms

• Amyotrophic Lateral Sclerosis (ALS)
• Oxidative Stress
• Neurodegenerative Disease
• Intravenous Therapy

Side Effects

Common side effects of Edaravone include bruising, gait disturbance, hives, and swelling of the limbs. More serious side effects may include alterations in the level of consciousness, thrombocytopenia, and acute kidney injury.

See Also

• List of ALS Medications
• Neurology
• Pharmacology

References

• Edaravone (Radicava) - ALS News Today. (n.d.). Retrieved from https://alsnewstoday.com/edaravone-radicava/
• Edaravone - DrugBank. (n.d.). Retrieved from https://www.drugbank.ca/drugs/DB01200

External links

• Medical encyclopedia article on Edaravone
• Wikipedia's article - Edaravone

This WikiMD dictionary article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski